These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 32772617)

  • 1. Eculizumab in the treatment of neuromyelitis optica spectrum disorder.
    Giglhuber K; Berthele A
    Immunotherapy; 2020 Oct; 12(14):1053-1066. PubMed ID: 32772617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
    Frampton JE
    Drugs; 2020 May; 80(7):719-727. PubMed ID: 32266705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.
    Pittock SJ; Berthele A; Fujihara K; Kim HJ; Levy M; Palace J; Nakashima I; Terzi M; Totolyan N; Viswanathan S; Wang KC; Pace A; Fujita KP; Armstrong R; Wingerchuk DM
    N Engl J Med; 2019 Aug; 381(7):614-625. PubMed ID: 31050279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies.
    Carnero Contentti E; Correale J
    J Neuroinflammation; 2021 Sep; 18(1):208. PubMed ID: 34530847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial.
    Palace J; Wingerchuk DM; Fujihara K; Berthele A; Oreja-Guevara C; Kim HJ; Nakashima I; Levy M; Terzi M; Totolyan N; Viswanathan S; Wang KC; Pace A; Yountz M; Miller L; Armstrong R; Pittock S;
    Mult Scler Relat Disord; 2021 Jan; 47():102641. PubMed ID: 33310418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Satralizumab in the treatment of neuromyelitis optica spectrum disorder.
    Duchow A; Bellmann-Strobl J
    Neurodegener Dis Manag; 2021 Feb; 11(1):49-59. PubMed ID: 33167776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Newly emerging type B insulin resistance (TBIR) during treatment with eculizumab for AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD): fatal outcome.
    Doubrovinskaja S; Korporal-Kuhnke M; Jarius S; Haas J; Wildemann B
    J Neurol; 2024 May; 271(5):2866-2870. PubMed ID: 37962590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging drugs for the treatment of neuromyelitis optica.
    Duchow A; Chien C; Paul F; Bellmann-Strobl J
    Expert Opin Emerg Drugs; 2020 Sep; 25(3):285-297. PubMed ID: 32731771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.
    Pittock SJ; Lennon VA; McKeon A; Mandrekar J; Weinshenker BG; Lucchinetti CF; O'Toole O; Wingerchuk DM
    Lancet Neurol; 2013 Jun; 12(6):554-62. PubMed ID: 23623397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging Targeted Therapies for Neuromyelitis Optica Spectrum Disorders.
    Valencia-Sanchez C; Wingerchuk DM
    BioDrugs; 2021 Jan; 35(1):7-17. PubMed ID: 33301078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder.
    Wallach AI; Tremblay M; Kister I
    Neurol Clin; 2021 Feb; 39(1):35-49. PubMed ID: 33223088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inebilizumab for treatment of neuromyelitis optica spectrum disorder.
    J Tullman M; Zabeti A; Vuocolo S; Dinh Q
    Neurodegener Dis Manag; 2021 Oct; 11(5):341-352. PubMed ID: 34486379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current Status and Prospects of Complement-Targeting Therapy for Neuromyelitis Optica].
    Kuroda H; Fujihara K
    Brain Nerve; 2019 Jun; 71(6):573-580. PubMed ID: 31171754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibody therapy for neuromyelitis optica spectrum disorder: current and future.
    Lin J; Xue B; Li X; Xia J
    Int J Neurosci; 2017 Aug; 127(8):735-744. PubMed ID: 27680606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hope for patients with neuromyelitis optica spectrum disorders - from mechanisms to trials.
    Pittock SJ; Zekeridou A; Weinshenker BG
    Nat Rev Neurol; 2021 Dec; 17(12):759-773. PubMed ID: 34711906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy and Safety of Inebilizumab, an Anti-CD19 Monoclonal Antibody, for the Treatment of Neuromyelitis Optica Spectrum Disorder: Based on the N-MOmentum Trial].
    Fujihara K; Sato H
    Brain Nerve; 2024 Oct; 76(10):1153-1160. PubMed ID: 39370840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Neuromyelitis Optica Spectrum Disorder].
    Misu T
    Brain Nerve; 2021 May; 73(5):475-482. PubMed ID: 34006678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD.
    Wingerchuk DM; Fujihara K; Palace J; Berthele A; Levy M; Kim HJ; Nakashima I; Oreja-Guevara C; Wang KC; Miller L; Shang S; Sabatella G; Yountz M; Pittock SJ;
    Ann Neurol; 2021 Jun; 89(6):1088-1098. PubMed ID: 33586143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eculizumab Use in Neuromyelitis Optica Spectrum Disorders: Routine Clinical Care Data From a European Cohort.
    Ringelstein M; Asseyer S; Lindenblatt G; Fischer K; Pul R; Skuljec J; Revie L; Giglhuber K; Häußler V; Karenfort M; Hellwig K; Paul F; Bellmann-Strobl J; Otto C; Ruprecht K; Ziemssen T; Emmer A; Rothhammer V; Nickel FT; Angstwurm K; Linker R; Laurent SA; Warnke C; Jarius S; Korporal-Kuhnke M; Wildemann B; Wolff S; Seipelt M; Yalachkov Y; Retzlaff N; Zettl UK; Rommer PS; Kowarik MC; Wickel J; Geis C; Hümmert MW; Trebst C; Senel M; Gold R; Klotz L; Kleinschnitz C; Meuth SG; Aktas O; Berthele A; Ayzenberg I;
    Neurology; 2024 Nov; 103(9):e209888. PubMed ID: 39353149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
    Nie T; Blair HA
    CNS Drugs; 2022 Oct; 36(10):1133-1141. PubMed ID: 36070074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.